<SUBMISSION>
<ACCESSION-NUMBER>0001140361-07-005351
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20070308
<ITEMS>2.02
<ITEMS>9.01
<FILING-DATE>20070309
<DATE-OF-FILING-DATE-CHANGE>20070308
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>BIOSANTE PHARMACEUTICALS INC
<CIK>0001023024
<ASSIGNED-SIC>2836
<IRS-NUMBER>582301143
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>001-31812
<FILM-NUMBER>07682251
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>111 BARCLAY BLVD STE 280
<CITY>LINCOLNSHIRE
<STATE>IL
<ZIP>60069
<PHONE>8474780500
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>111 BARCLAY BLVD STE 280
<CITY>LINCOLNSHIRE
<STATE>IL
<ZIP>60069
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>BEN ABRAHAM TECHNOLOGIES INC
<DATE-CHANGED>19991027
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>earningrelease2006.htm
<DESCRIPTION>2006 EARNINGS RELEASE
<TEXT>
<html>
  <head>
    <title>
    </title>
<!-- Licensed to: EDGARfilings-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff"><br>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">__________________</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>FORM
      8-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Current
      Report</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Pursuant
      to Section 13 or 15(d) of the Securities Exchange Act of
      1934</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">__________________</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date
      of
      Report (Date of earliest event reported): </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>March
      8, 2007</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>BIOSANTE
      PHARMACEUTICALS, INC.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Exact
      name of registrant as specified in its charter)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Delaware</strong></font></div>
            </td>
            <td valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>001-31812</strong></font></div>
            </td>
            <td valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>58-2301143</strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(State
                or Other Jurisdiction of Incorporation)</font></div>
            </td>
            <td valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Commission
                File Number)</font></div>
            </td>
            <td valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(I.R.S.
                Employer Identification Number)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 45pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="top" width="40%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>111
                Barclay Boulevard</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Lincolnshire,
                Illinois</strong></font></div>
            </td>
            <td valign="top" width="40%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>60069</strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="40%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
                of Principal Executive Offices)</font></div>
            </td>
            <td valign="top" width="40%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Zip
                Code)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(847)
      478-0500</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Registrant&#8217;s
      Telephone Number, Including Area Code)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>N/A</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Former
      Name or Former Address, If Changed Since Last Report)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Check
      the
      appropriate box below if the Form 8-K filing is intended to simultaneously
      satisfy the filing obligation of the registrant under any of the following
      provisions:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings 2, serif">&#163;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Written
                communications pursuant to Rule 425 under the Securities Act (17
                CFR
                230.425)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings 2, serif">&#163;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Soliciting
                material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
                240.14a-12)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings 2, serif">&#163;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pre-commencement
                communications pursuant to Rule 14d-2(b) under the Exchange Act (17
                CFR
                240.14d-2(b))</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings 2, serif">&#163;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pre-commencement
                communications pursuant to Rule 13e-4(c) under the Exchange Act (17
                CFR
                240.13e-4(c))</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 81pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Section
      2 - Financial Information</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Item
      2.02. Results of Operations and Financial Condition</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
      March
      8, 2007, BioSante Pharmaceuticals, Inc. publicly announced its financial results
      for the year ended December 31, 2006. For further information, please refer
      to
      the press release attached hereto as Exhibit 99.1, which is incorporated by
      reference herein. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      information contained in this Item 2.02 and Exhibit 99.1 hereto </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">shall
      not
      be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange
      Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the
      liability of that section, and shall not be incorporated by reference into
      any
      filings made by </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BioSante
      Pharmaceuticals, Inc. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">under
      the
      Securities Act of 1933, as amended, or the Exchange Act, except as may be
      expressly set forth by specific reference in such filing.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Section
      9 - Financial Statements and Exhibits</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Item
      9.01. Financial Statements and Exhibits. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Exhibits</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="top" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit
                No.</font></div>
            </td>
            <td align="justify" valign="top" width="59%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Description</font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="10%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">99.1</font></div>
            </td>
            <td align="justify" valign="top" width="59%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Press
                Release issued March 8, 2007</font></div>
            </td>
          </tr>

      </table>
    </div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: -0.35pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURE</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, the registrant
      has
      duly caused this report to be signed on its behalf by the undersigned hereunto
      duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 216pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>BIOSANTE
      PHARMACEUTICALS, INC.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 216pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
      /s/
      Phillip B. Donenberg</u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 234pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Phillip
      B. Donenberg</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 234pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Chief
      Financial Officer, Treasurer and Secretary</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dated:
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">March
      8,
      2007</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>BIOSANTE
      PHARMACEUTICALS, INC.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>FORM
      8-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Exhibit
      Index</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Exhibit
                No.</strong></font></div>
            </td>
            <td valign="bottom" width="41%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Description</strong></font></div>
            </td>
            <td valign="bottom" width="25%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Method
                of Filing</strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="11%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">99.1</font></div>
            </td>
            <td align="justify" valign="top" width="41%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Press
                Release issued March 8, 2007</font></div>
            </td>
            <td valign="top" width="25%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Furnished
                herewith</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
  </body>
</html>



</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pressrelease2006earnings.htm
<DESCRIPTION>2006 EARNINGS NEWS RELEASE
<TEXT>
<html>
  <head>
    <title>
      2006 earnings news release
</title>
<!-- Licensed to: EDGARfilings-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff"><img src="biosantelogo6.jpg" alt=""><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>BioSante
        Pharmaceuticals, Inc. </strong></font></div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>FOR
      IMMEDIATE RELEASE </strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
      Amex: BPA</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>BioSante
      Pharmaceuticals Reports </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>Net
      Profit of $2.8 million for 2006</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>And
      Investor Conference Call </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>LINCOLNSHIRE,
      Illinois (March 8, 2007)</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      --
      BioSante Pharmaceuticals, Inc. (Amex: BPA) today </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">announced
      its 2006 financial results. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      the
      year ended December 31, 2006, BioSante recorded net income of approximately
      $2.8
      million or $0.13 per basic and diluted share for the year ended December 31,
      2006, compared to a net loss of $9.7 million or ($0.50) per basic and diluted
      share for the same period in 2005. The company&#8217;s cash, cash equivalents and
      short-term investments as of December 31, 2006 were approximately $11.5 million,
      compared to $9.1 million at December 31, 2005.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#8220;2006
      was a very important financial year for
      BioSante,&#8221; said Stephen M. Simes, BioSante&#8217;s president and chief executive
      officer. &#8220;We recorded our first ever year <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">with
      net
      income which was </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">primarily
      the result of the revenue from our</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      agreement </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">with
      Bradley Pharmaceuticals, Inc. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">for
      the
      marketing of Elestrin&#8482; (estradiol gel). Due to a $2.625 million upfront
      licensing payment from Bradley and a $7.6 million </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">private
      placement completed</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      in July
      2006, we were able to increase our cash balance from a year earlier. Based
      on
      our current cash balance and the additional milestone payments already due
      from
      Bradley, we believe we are in a solid financial position to move forward with
      our LibiGel development program and our other operations. We look forward to
      our
      investor conference call scheduled for Friday, March 9, 2007 at 9 am ET,&#8221; Simes
      concluded</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BioSante
      will issue its development highlights and host its 2006 earnings conference
      call
      Friday, March 9, 2007. The conference call will include a discussion of the
      company&#8217;s development activities, financial results and current news. Details
      are provided below</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">*******************************Conference
      Call Information*****************************</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BioSante
      Pharmaceuticals will host a conference call to discuss its 2006 financial and
      development accomplishments.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">When
      -
      Friday, March 9, 2007 at 9:00 a.m. ET</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Website
      for listen only </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>http://www.vcall.com/IC/CEPage.asp?ID=114862</u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Live
      Domestic and Canada call in: - 877-407-0781</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Live
      international call in - 201-689-8568</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">24
      hour
      replay Domestic and Canada - 877-660-6853</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">24
      hour
      replay International - 201-612-7415</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">24
      hour
      replay, web access </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>http://www.vcall.com/IC/CEPage.asp?ID=114862</u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Replay
      pass codes, (both required for playback)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Account
      #
      - 286 Conference ID - 234347</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">**********************************************************************************</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>About
      BioSante Pharmaceuticals, Inc. </em></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BioSante
      is developing a pipeline of hormone therapy products to treat both men and
      women. These hormone therapy products are gel formulations for transdermal
      administration that deliver bio-identical estradiol and testosterone. BioSante's
      lead products include Elestrin&#8482; (estradiol gel), developed through FDA approval
      by BioSante, indicated for the treatment of moderate-to-severe vasomotor
      symptoms associated with menopause, and LibiGel</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>&#174;</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      (transdermal testosterone gel) in Phase III development for the treatment of
      female sexual dysfunction (FSD). The current market in the U.S. for estrogen
      and
      testosterone products is approximately $2.5 billion. The transdermal gel
      formulations used in the women's gel products are licensed by BioSante from
      Antares Pharma. The company also is developing its calcium phosphate
      nanotechnology (CaP) for novel vaccines, including hepatitis B, avian flu and
      biodefense vaccines for toxins such as anthrax, as well as a system for
      delivering drugs via alternative routes of administration. Additional
      information is available online at www.biosantepharma.com.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      news
      release contains forward-looking statements within the meaning of the Private
      Securities Litigation Reform Act of 1995. The statements regarding BioSante
      contained in this news release that are not historical in nature, particularly
      those that utilize terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;likely,&#8221;
&#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; &#8220;believes,&#8221; &#8220;plans,&#8221; &#8220;hopes,&#8221; or
      comparable terminology, are forward-looking statements. Forward-looking
      statements are based on current expectations and assumptions, and entail various
      risks and uncertainties that could cause actual results to differ materially
      from those expressed in such forward-looking statements. Important factors
      known
      to BioSante that cause actual results to differ materially from those expressed
      in such forward-looking statements are the difficulty of developing
      pharmaceutical products, the success of clinical testing, obtaining regulatory
      and other approvals and achieving market acceptance, and other factors
      identified and discussed from time to time in BioSante's filings with the
      Securities and Exchange Commission, including those factors discussed in
      BioSante's most recent Forms 10-K and 10-Q, which discussion also is
      incorporated herein by reference. All forward-looking statements speak only
      as
      of the date of this news release. BioSante undertakes no obligation to update
      or
      revise any forward-looking statement, whether as a result of new information,
      future events or otherwise.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 9pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>CONTACT:
      Phillip Donenberg</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 9pt" align="justify"><font id="TAB1" style="MARGIN-LEFT: 54pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>BioSante
      Pharmaceuticals, Inc.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 9pt" align="justify"><font id="TAB1" style="MARGIN-LEFT: 54pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(847)
      478-0500</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 9pt" align="justify"><font id="TAB1" style="MARGIN-LEFT: 54pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>donenber@biosantepharma.com</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
  </body>
</html>



</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>biosantelogo6.jpg
<DESCRIPTION>LOGO
<TEXT>
begin 644 biosantelogo6.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`"/`5(#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#S?_A-/%?_
M`$,VL_\`@?+_`/%4'QKXK'_,S:U_X'R__%5A4'I7UWLX=D(]4T_PU\6=4TZU
MO[76]1:WN(EFC<ZP>C?,,C?Z5/\`\(7\8O\`H+ZA_P"#IO\`XNO9O`9SX!\/
M$\G^S;?G_@`J]J'B'1](=4U/5K&R=QN5;FY2,M],FO`EC:BFXJ*T\AGA?_"%
M_&+_`*"^H?\`@[;_`.+I&\&_&5!QJ6J2?36L?^SU[5_PF_A7_H9M&_\``^/_
M`!J>R\3:#J<HAL-;TRYD)QM@NXW;\@33>-K+>*_\!)LCYNUG_A9_AV)I-6OO
M$EO&HYF^W2/&OU=6V_\`CU87_":^*_\`H9M9_P#`^7_XJOL-X8I$9'C5D;[R
MLN0?J*^7/BMX.@\(^*`;)%CL+Y3-#$3PA'WU'H.5Q_O>U=>$QD:SY)Q28[%W
M0M(^*7B72H]2TS7-2FM9&*ASJ[*?E]O,JMXEC^(WA*&";6->U6);ABD6W5'?
MISV<=J]-^$>NZ19?#VU@O-5L;>59I,I+<(C8)X^\U<]\==7TS5--T9+'4;2[
MV3NS"WF63:-O7AJBG7J2Q'LW%6]`L>7_`/":^*_^AFUG_P`#Y?\`XJC_`(33
MQ7_T,VL_^!\O_P`56%17K>SAV0&[_P`)IXK_`.AFUG_P/E_^*H_X33Q7_P!#
M-K/_`('R_P#Q585%'LX=D!N_\)KXK_Z&;6?_``/E_P#BJ/\`A-?%7_0SZS_X
M'R__`!587UK;\'^'I/%7BFPT@$A)7S*0,8C'+?CBE-4X1<FEH!IZ3JOQ"U^;
MRM)U;Q%>/GDPW<K*OU;<%%=7%X/^,;KN;4=5CS_#)K?/Z/7O>EZ39Z+IT6GV
M%O'!;QKM"#O[D]S]:9J.M:9I$8;4-3L[0'^*YG6//YUX<\?)R_=P5O0+'A/_
M``A?QB_Z"^H?^#MO_BZ/^$+^,7_07U#_`,';?_%U[3_PF_A7_H9M&_\``^/_
M`!H_X3;PK_T,VC?^!\7^-+ZY6_D7W"LCQ8>"_C$2!_:^H<_]1MO_`(NN)U#Q
M/XRTW4)[&Z\1:PDT#F.1!J,IY'H=U?3X\;>%,_\`(S:-_P"!T?\`C7RIXKFB
MN_%VK2V[QS1/=,RO&=P(]0177@:LZT^6I%?<.Q)_PFOBO'_(S:S_`.!\O_Q5
M'_":>*_^AFUG_P`#Y?\`XJL*BO3]G#L@-W_A-/%?_0S:S_X'R_\`Q5'_``FG
MBO\`Z&;6?_`^7_XJL*BCV<.R`W?^$T\5_P#0S:S_`.!\O_Q5'_":>*_^AFUG
M_P`#Y?\`XJL*BCV<.R`W?^$T\5_]#-K/_@?+_P#%4?\`":>*_P#H9M9_\#Y?
M_BJPJ*/9P[(#=_X33Q7_`-#-K/\`X'R__%4?\)IXK_Z&;6O_``/E_P#BJPJ*
M/9P[(#=_X37Q5GGQ-K.._P#I\O\`\57<:?X9^+.K:;;:A::UJ+VUU$LT3?VN
MPRK#(_C]Z\JK[!\"`?\`"O\`P]Q_S#H/_0!7!CZOL$N1+7R%$^<?$&I>//"V
MIG3M6\0ZM%=>6'`35'88)SZ^E9)\:>*_^AFUG_P/E_\`BJZWXY<?$1L<?Z+%
M_6O-:ZL.HU*49M*XS=_X33Q7_P!#-K/_`('R_P#Q5'_":>*_^AFUG_P/E_\`
MBJPJ*U]G#L@-W_A-/%?_`$,VL_\`@?+_`/%4?\)IXK_Z&;6?_`^7_P"*K"HH
M]G#L@-W_`(33Q7_T,VL_^!\O_P`50?&OBO'_`",VM?\`@?+_`/%5A4'I0Z<.
MR`^TO#TLDWAK2I97:21[.%G=SDL2@))/<T4WPU_R*NC_`/7E#_Z`**^3G\3&
M?%]!Z44'I7UXC[!\"?\`)/\`P]_V#;?_`-%BO(/VA?\`D/:(>_V:4_\`CU>O
M^`_^1`\/?]@VW_\`0!6?XO\`ASH_C6ZM+G5)KR-[9"L8MI%'!]=RFOF:-6-'
M$.<MD,^3MH]!3E=XG$B,R.ARK*<$'V-?1_\`PH3PC_S]:M_X$)_\15BP^"/@
M^PO5N"M]=[.1!<3`I^(503^=>I/-*#6E_N%8[/PU<W-YX6TFZNRQN9K*&24G
M@LYC4GZ<UY#^T*Z9\/PX!FS,PYZ+\O\`];\C7L>J:K8:!IDEY?SI;6L(^9V[
M>@P*^5O'OBV7QEXEDU'8Z6L:&*UC/41]C]3D_E7!E]-SKJ:V0I'9^!/A#I?B
MWPI!K-SJ%W#/+(X*QHI'!QT-9/Q-^'%CX&M=/FLKNXG-T[QL)5`Q\OM7K7P6
M`_X5M9#`_P!?+_.N:_:%`&F:&<?\O#_^@UO3Q-5XODYM+VL,\%->D^$/@[J_
MB.WCO[^4:;8N`8RZYDE'J%[?C^M0_"+PA#XD\5&YOH=UCIX$KHXR)'/W`1Z<
MYQ[5]*7][:Z78S7MU(L5O"A=V/8"ML;C94Y>RI;]PL>:Q?`/PI''^]N]7E?N
MWG(/TV5EZO\``&Q>-VT;5KF*3^&.\"NK_BHR/RK+U3X^Z@]\W]D:3;BV1L*;
MG<TCCUPO`KN?A]\3K;QI(]C<V_V+4D'F>6&W)*OJI_I7)+Z[3C[63T%H?.WB
M#P[J?A?4FT_5+1H9NJ=U<?WD/<>QKO?@/#')XYN9&P3'9N5R.F2!_(FO8?B%
MX1M_%WA:XM&C'VN)6EMI".5<=OQKP/X6Z]%X=^(%J]X1%#<!K>7<,;">!GZ'
MK76L2\3A9I[H=CZGN7:*UFD099$9E'N!7Q;J=_=:KJUS?WDC27,DC,2_)7D\
M9/85]J'YAZ@CH.017FNL_!3PSJVHS7<<MY9R2L6DCA92ASZ`CBO/P.(IT)/G
MZC/FC`]!1A?05]#_`/#/V@_]!;4?R3_"D?\`9^T(J<:OJ`]\)_A7J_VG0[L#
MYYVC^Z/RI<#@=NPKUWQ#\"=1TZUDN=%OTU':,^3*HBDQ['.TUY'+%)!-)%*C
M+(C89&&"I[@UTT<13K?PV(]6^'OPHT[QEX535;K4+NWF,SQ%8T!'RGWKJ_\`
MAGS1?^@S?_\`?"UYWX/^*VH^#="_LNTTZTN(Q*\F^20CD\UT'_#0.M_]`33\
M^OFM7GU88YS?(]`.B/[/NB@'_B<ZAT_N+6)K'P!O(8'DT75TNG`R(;F(Q[O8
M,,C/Y4V+]H+5DD7S]!M&3IA9F4GZ96O7_"?B:S\8Z%#JEHCHK$JT;CF-AU'O
M7-.KC*'O5'H,^1+RSN=.OI;.\@>&XB8J\;+\P(_I[UU'PZ\(6WC/Q#)IMW<S
M6\2VYF#Q`$G!`[_6N^^/VBQ))I>MQ18EDW03'U`P5SZ]36'\!O\`D>[DXR?L
M3_\`H2UZ$L3*>$]K'1BL=C_PSYHG_0:U#_OE/\*/^&?-$Y_XG6H?]\I_A7I7
MB36#H'AV^U18?/:TB\P1EMN[G&,UX^/VB+C_`*%>+_P./_QNO,I5,953<&W8
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MD3MC=%:P%]O_``-F'/T%=Y\*_"<?AKPA;221XO[Y!<7+G[PR/E3/LN./7)J'
MX@?$ZV\%7$-A%9M>ZA-'YWE%MJQKR,L:FMC*U2K[.B!@#]GW10/FUK4&/KY:
MC^E17?P"T:"SGF76+XM'&S@,BXR!GFL(_M!ZPQ.-"LU`/>5S_P"RTR?X^ZK/
M;2PMHEHJNC*2)6R,C&?NTU3QU]63H>1##X;/!!/3'KC^5!Z&E"E!M(Q@;>N>
MA(/\Z0CBO:7PZC/M#PU_R*NC_P#7E#_Z`**/#7_(JZ/_`->4/_H`HKY&I\;&
M?%]!Z44'I7UPC[!\!_\`(@>'O^P;;_\`H`K!\?\`Q*B\"7]E:R:=)>&ZC:0%
M9`NW:W-;W@/_`)$#P]_V#;?_`-`%>0_M`1/)K^C&.-W7[+*"54G'S=\"OF:%
M.%3$\L]AFG_PT-!_T+\G_@2O^%6;+]H#3+BZ6.]T:Y@A;K)'(),?45X'Y,O_
M`#SD_P"^#5F#2[^_NEMK:TN)IY6VJJ1L2WX$<?C7K3P&%4?^"*Y]F$6>J:>-
MRQW5I<("`RAE=6Z<'BOF;XJ^#+?PAXCC-DNW3[Y#+$A))B9?OKG_`($N/][V
MKZ,\,Z?-I/A?2M/N,":WM(HY,'(W*H#8_&O*?VA7C%GH,;<2F29A_NJ!_4K7
MF8&<HXA16S&=5\%N/AK9?]=I?YUS7[0W_(,T+_KX?_T&NE^"_P#R36R_Z[2_
MSKFOVAO^09H7_7P__H-72_W[YB+7P!M8XO"VI70_UDMT%8_[J\?^A&M/XX7<
MMM\/7AC.U;BYCB<C^[G)_/'ZUSW[/NJ1M9ZQI3,/,619T7N1T8_GBNV^*7A^
M?Q#X#O;:VCWW,)%Q&O\`>*G)7ZD9%35]W&7EW`^4\5T?@"[DLO'FARQMRUVB
M'`QP3S7.N"K%2""#A@1@JWH0:[OX2^'9]:\;V5RL9^RV,OGRR8^7(Y"_GBO;
MQ$HJE)R86/J;`%?&OBJ$6WC#5X4X5;V0?FQ:OL6>=+6WDGE8*D:EF).,`"OB
M_6+O^U=>OKQ?F%S<22Q@@Y(+?*..^*\G*HOGD^@I'=^&/C'XAT"VCM+M(]3M
M8AA1.VR11Z;QU_$5V$?[0ED5'FZ!<@GLLJFO"_*G_P">$G'^R>*/*GSS!)_W
MP:]">!PTW=K\1GO/_#0FF?\`0!O/^_J?XU=TGX[Z%?7B6]WI]Y9+(VT3$JZ`
MD]R#D5\\^3/_`,\)/^^#5_2M`U/6[^.RL;&>69VQCRV^4>I.!C'UK*>`PRC?
M]0N?9B.K`.K`A@"".^>E?,GQIT>/2_'[W$*K''?0K,5QQO'#'^5?2=C`;33[
M6W?YGBA2,GU(`']*^?\`X_3))XKL8$8;X;,[Q[$YKS<O;C7T&RIX`^$T_BNT
M74]0N&LM-=CY2H/WDH'4C/`'O7IUO\$?!L2`/!>3^\D^?Y`5VF@6<-GX>T^W
MB4*B6T:C`P/N@UY'\4_B5XAT+Q7)HVDS):Q0Q(YD\L,[EAGO5^VQ&)J\L)6`
M[`?!?P2IS_9TPQ_T\-_C73^'?#&E^%;!K+287B@9BY#N6Y/UKYK_`.%N>.#Q
M_;;?]^(_\*]H^$7B35/$_ANZO-5NS<3I<&-6*A1C`[`48K#XFG"]65UZ@97Q
M\'_%(6/'_+X/Y&N(^`W_`"/5S_UY/_Z$M=Q\?/\`D4;'_K\_H:X?X"_\CW<_
M]>3_`/H2UM1_W&0CVGXBC_BWFN<#_CV/\Q7R*.*^N_B+_P`D]US_`*]C_,5\
MB5KE/P2%(]F_9ZR=5UW/_/"#_P!">O0?C"!_PK#5>!P8S]/G6O/OV>?^0KKO
M_7"#_P!">O0?C#_R3#5?K'_Z,6N?$_[ZOD,^5R/;M7V%X#_Y)_X=/?\`LZ#G
M_@"U\??X=Z^P/`7/P\\.GC_D&P?^@"M\W^"`HGA'QS`_X6&P_P"G6+^M><Q1
M"66.(\!V"?@37IWQXLY(/',%RZL(I[-2CXX)5BI7Z]_QKR[+)\Z\,OS#Z]JZ
M\(T\.DNPS[>C0)$J*,*!@5R7B'X:^'/$^JMJ.IV]Q)<2($)68J`!TXKH])OX
MM3T>SU"W<&&XA216]05S_6O)?BGX[\5^$/$R0V$D4>G36ZR0EXMP+9P1GU&"
M<>A%>#0A4E5Y:;LQG2#X)>#`,"UNL?\`7P?\*KWWP6\'0Z?<RQVMR'2)V4F<
M]0"1VKRK_A=OC3_G\L__``''^-,F^-/C&:"2*2[M"CJ58"``D$<]Z]%8;&7U
MG^(C@,\9!(#'</8<C]<4'H:4`C*_W3M(Z9.<_I2=C7LI>Z(^T?#7_(JZ/_UY
M0_\`H`HH\-?\BKH__7E#_P"@"BOD:GQLH^+Z#THH/2OKA'V#X#_Y$#P]_P!@
MVW_]`%;LEO#,P,L$;D<`L@.*^:=*U_7HM&LH[?7-0BB6%!'&CC:H].F<5;_X
M23Q%_P!##J/_`']7_P")KY^>!GSMW%SH^BOL=M_S[P_]\#_"G1P10Y,421[N
M3L4#-?.?_"2>(_\`H8=2_P"_J_\`Q--;Q%X@8;3X@U0CU\X#_P!EI?4:C^T'
M.CZ#O]2LM)M'NKZYBMX4&YI)6``_QKY=^)?C,>,_$OGV^X:=:H8[;/5Q_$Y'
M;=CI_LBH]7TZ^U0M)-J=U<R#H+F0L/P!Z5R<L3V\[QNI61>H-=^#P4:4N=N[
M"]SZ=^"P_P"+:V7_`%WE_G7-?M#?\@O0_P#KX?\`]!KS_P`-:UK-EHD<-IK%
M];6X9L1Q.`H_,52\8ZGJ>HPVBW^HW5WL8[?/<':?P`K.GA9+$^TOI>X^;6QF
M^%?$EWX3\0V^KV7.S(DC)QYL9^\I]_3Z5]4>&_%6D^*[!+K3;A7XR\3'YXSZ
M$?UKX\(W_*HSS72:+IM[93+>17EQ9SCH(6*OCT)'6M\9A(5?>O9DWL?2VJ?#
M_P`*ZS=M=WVB6TLY^\Z[E)/J<8%;&FZ3INAV?V;3[2&TMU&2L:X'U)[GZUXA
M;>.O$UM"L2ZM+*>FZ0*Q'Z5C:[K.M^((C'>ZU>[#_P`LU8(OXA:\Y8*K+W92
MT'SHZKXL?$FW-C-X=T6<2R2?+=7,;951_<!]3W/:O*?!*AO&^A(0"OVU/E(R
M.OI67?:?/82!95Q&?NLHXI=+EE@U:VEBD>*5)05=?X3_`(UZU+#QI4>2`7/M
M/[+;_P#/"+_O@4?9;?\`YX1?]\"OG4^)/$>?^1AU+_OZO_Q-)_PDGB/_`*&'
M4O\`OZO_`,37D?4JG\P<R/HO[+;_`//"+_O@4](TC7$:*H]%&*^<3XD\19_Y
M&'4?^_J__$U%/KOB"=&1O$&IX/<2X_D*/J$WU#F1[UX@\3:3X9L9+O4[N.)5
M&0A.78^@'6OE#Q7KTWBKQ%=ZM.K(+@D(I/W8QP!5K5-'N[EVNC>3W<GK/(6;
M'L37.LN/E*G*MSNKT<'@X4M6[L5^8^J?AMXPM/%'A>R02J+^WB$4\.[GY>,C
MVK;UGPCH'B"19-6TFWNI5P`[@AL>Y&*^5=#TZ[#K?1W4]J<X5H7*L?Q%=K'K
M_B!%"C7]3&.,^:#S^5<E7`6J-TY#YTCV/_A5W@D'/_".6O'N_P#C6WHOA_2_
M#UHUMI-BEI`SERD9)!/KS7@G_"2>(_\`H8M2_P"_J_\`Q-)_PD?B(#_D8=1`
M'_35?_B:RE@JLEK,.=';_'S_`)%"Q_Z_/Z&N(^`O_(]W'_7F_P#Z$M<_XNU;
M5;_3HX[[5+V[B$N0L[`J#CM@"LOPE>WUAK$CV5W-:2F(C?`P#8ST.17=3PS6
M%=.^XKZW/IWXB#_BWFN<?\NS?S%?(F.*]%UGQ!KUQHUW%<:Q?RPE,-'(Z_,/
M?`Z5YT1Q5X##NDFF]QWN>R_L\_\`(6UW_KA!_P"A/7H7QA_Y)CJOUC_]#6OG
MWP?J-_87=X=.OYK-I%`)A8`G!/7(K:\2:UK5UH=Q!=ZM>W%NY7,<SC:2/H*Q
MK824L3[2XN=(X`\`\9]O6OI+X.^+K;5/"UOHDTR+?V'[E49L>;&/ND?AQ^%?
M-N#VP#6KHNGW%Q,+N*:2V"$;9(V*L"/0CI77B\/&M3LV.]CZ[UC0-*U^W$&J
MZ?#=1J?E$@Z9]".?2O%/C)X.\/\`AK1--GT?3([.66X8,R;CD;1V)-9,.O:_
M!&J+X@U,(HQGS0?S)%8'B_5M2OK.U%_JEW=QI,2HE;(!QVP!7GX?"U(5$U+8
M.9'<?"3XDVVG6\?AO7)Q%&IQ9W).4'_3,GT'8_AZ5[5<V.FZY9@75M:WMN<E
M=ZB0<\9![?A7QK9:?+?2M'"H8+U)'`'N*[+25U31T"VVM:A",<I%*0H^@.:U
MQ.`BY\\)68<Z1]!'X>>$B<GP_9$GT0C^M5K_`.'WA2/3KITT"S5EA<@A3D$*
M?>O'QXD\18VCQ!J0`[F5?_B:9/XC\0M!*K:_J#*4(*F08(QT/RUS+"5D_C#F
M1YAG*].><=^,"D/0T`G;NY.0<C`'?K0>_%>\E[H7/M#PU_R*NC_]>4/_`*`*
M*/#7_(JZ/_UY0_\`H`HKY&I\;*/B^@T4&OKA';Z=_P`@RS./^6256U35GTZ6
M-!`CJR[LDU9T[_D&6G_7)*Q?$B,]U`R*Q&S^%<URQ492U,8_$+_PDLO_`#Z)
M_P!]4Z/Q/EE$MJ-O^R:PO*D_YY2?]^S3H[:>4JB0R_-_L5MR0*Y4=S&RR1AQ
M\RNNX$=JY_Q+"JSP3J!N?Y3[UNVD3P64$3D%XTV\5@^)95+V\2L-R_,U94_B
MT)C\1HZ%_P`@F,CU:J?BGF*#//S5<T+_`)!,?U:J?BC_`%,'^]50_B%?:*F@
MV23WCS.N4B7TXW5T]S<1VD$DTAPJ#-8_AM,6$K=RW-2>(79=,(`X=U6B>L[`
M]78RI]?O)9&9&1$[#&<5I:3K4EY-]GN0-_4$=#7,8Z\59L79-1MW7J)`#6DJ
M<4KE2BN4Z^_M4O;.6%NNWY3_`':XR"0V]R'9.4;)'TXKO<#GBN$OD"7\^T_\
MM#4T&3$USXE?_GV'YT'Q*W_/L/SK!"L3@#=3Q!,5SY,A7U$9JO9Q'9&V?$K\
M_P"C#\ZF@\2H\BK-;,H[$'I7/FWG'_+"3_OD_P"%2V]A=SR*B0R`'N4QBIY(
MBY4=OC+;L[E(SD5R>OVZP:@VW`$@SS75HGEQ1KD':FVN:\3-_IT8'WE3FLZ7
MQ!'>QT=N@2VC1>-J*?TK#U;5KFSO6AAV(JC.-N<U>TB\2\LT3<OF(-I!/)JW
M<V-M=E3-"CL!C=TQ19*7O(E>[+4Y8:]J(_C3_OFMW1+N6]LVEG?>X8CIBI/[
M$T__`)]Q^9JS;6D5G$T4*!%)S3G*+5D.31E^)O\`CQC_`.NE4?#H_P")@P[>
M5_6K_B;_`(\(_P#KI5#P[_R$3_UR_K37P#C\)N:F!_9ESQ_RSKBFX4_2NVU/
M_D%W/_7.N(;[IX[4Z!43?\.#_2+L>P_F:TM=`_LJ;IU%9OAS_CYO/H/YFM/7
M?^05-]12G\9+^(X_N"<8[UVFDQB+2[0+_P`\P?KG-<41QVZ5VVG#_B6VO_7%
M?Y&JK[#D4=;U6:QE6&WP)"-Q;'05@W6I75W&%E8-Y?(XQ5OQ!_R%3_NUEH`S
M@'H2,U5.*Y;@E[IV6EVB6>GHJJ2S#>Q[U5UC5GL)5MX8U:7&XL>PK8"A<*O`
M`'\JKSV%G/-YDEO&[8P20:P37-J1U.<.OZ@>\?\`WQ2'7K]@03'@CGY.U=#_
M`&1I_P#SYP_E3)=)L!#(5M(@0I(('3BK4X]BKHXWD*-PRPSG\:0C@T'/S8&%
M#$4'H:WZ&A]H>&O^15T?_KRA_P#0!11X:_Y%71_^O*'_`-`%%?(U/C8SXOH/
M2B@U]<([?3_^09:_]<DJT1GMG\*JZ=_R#;;_`*Y)63XAGF@GA".Z;E_A:N5*
M\C*UY'0;?]G]*7&.@QCO7"?;;K_GYD_.GP:E?0,K)</N]":T]DQ\IV=V9UMF
M:WC1IA]T$UQ$\DLMS(T^?,W?-N'2NV@<S6R3E"ID7=CTKGO$ENL=U%,J\2KA
MO^`U-)V=@CO8T]"_Y!,?U:J?BC_4P?[U7-!!.DQ\=VJGXH'[J#C^*G'^('VA
M/#4ZJ9H&'SL-ZBM75+,WMC+$@P^,K7&VTSVUPDT;8=6R0?2NOL=3M[Y%VL$E
M[HQY_P"`^M$XM.Z"4=;G&R1O&[(X967^\*U-"T^2XO5G*8BC.=S?Q5U+P12'
M+Q(Y]2M.<QPKEF6-%_O'%#JMJP<XCN(XG<G`5>I[UQ$<<E_?F-/O2R$Y'\-:
M6L:PLZFWMV_=Y^8_WJC\.HK:D7/\*$TXIQ5V-*RN;]IIMK91J$B4M_$[=35W
M&!P,#VI'.U6;&2`37$7.H7=S.9&E<`G@!L;:B*<NI*5SN,'WHP1R,@^M<%]I
MN/\`GO)_WU09YF_Y:R?]]57L/,?*=K<7EO:0M)+(@/\`<_B/X5QE]=M>WKS,
M"N_A#Z"H22W4DGU-'?\`&M(041K0%8HV5.T]>#BK(U2]5<"ZE7\0:W]`A633
M,O"K'>><9K4^SP_\\(_P2IE42=K!*1QW]KW[?=NI#[8%=/I'VIK)9+HN[L>`
M_&*NK;Q)]R%!^%1SW$-NF9I$1?\`:;FLY24E9(3=S(\2G%K`.[L:I^'?^0DW
M_7+^M5=3U'[?=AE&(8^%5N"?>K7AP'^T'XY\JM+6AJ%M+&[J?_(+N/\`<KBM
MK>A'_`:]!*Y&"N?PI/*7^X/RK.-3EZ`G8P/#=NZB>:0%4;H",$U=UYE72)">
MI8"K\CQP+F1@BCNQZ5S6N:E'<M%!"<Q(<D^I]:(WE*X;R,4]Z[C31_Q+;3_K
MDO\`(U0T&VBDTI6>*-\L>66M=454"*I11T`%.L[JP2EI8Y7Q%QJQ_P!VLK&3
MBN^:V@D;+P(Y]2M8GB*"*&TB9(U7+=`O6KISO[H1E?0U[>=9[6.=.3(H;'Z5
MC:Y-?VUT9(II5A*@97H#Z57T?5A:*;:X&82<JP_A]JZ2.2"Y0&-TD4CH#FH:
M<'<-G<XW^U;[_G[?_OK_`.M0=5O3]ZZ<@]1G_P"M79_9X_\`GFO_`'S4<\$8
MMY2(E^XW\/M351=@N<(2Q!W'.3FE/0TI'S-Q_$:0]#6[-#[0\-?\BKH__7E#
M_P"@"BCPU_R*NC_]>4/_`*`**^1J?&QGQ?0:*#TKZX1V^G?\@NS_`.N253U?
M2IM0EB>)U&U?XJ2RUBPAL8(Y+A494VMPU6?[9T[_`)^E_P"^&KF?-%W2,?>Y
MC%_X1J[_`+\7Y4Z/PU.73S)T"_[(K8_MG3O^?I?^^&IC:WIH_P"7G=_P!J?/
M/L/FD:"1JD:Q*N%5>]<YXGF1IH84^\B[FJW<>([=$98$:5O]JN9FFEFG:61M
MTK-NW55*#O>0XQUN:EEH]S>VRS1W*QH[;>AJ'4M.N+)(C+,LFYMORC-:FD:C
M96VG)'-*%DW;L;:K:_>6MW'`+>0,R-NX6G>7-L/4Q,=Z.AR.".GM1VHK4LG6
M]NE7:MQ*JCT;-,>>:9MTK.S>C-4>*"*!6#M6GH,ZQ:HF[Y0XVBLRE!(((Z@Y
M%*2NK$GH)`(Y%<[=>&F>4O;3!06+;66EL_$:;5CO(W/8.HK0&MZ<RY-SC_>2
MN:TX["Y7$Q_^$:N_[\7Y4?\`"-7?_/2+\JVCK.G?\_2_]\-1_;.G?\_2_P#?
M#5?//L+FD8O_``C-X>/.B_*LJ2-H)7C8@LC%3MKK_P"V=.S_`,?2_P#?+5R5
MVR/=S,C!HRY8$>]:0<GN7&_VB(2R(,`D?0TOG3?\]6_.FXHQ5E"^;+_ST;\Z
M"2?O$GZTE%`!CO2@E3E20?8XI**`'>=+_P`]6_.CSI?^>K?G3:,4"L*69ARQ
M/U-)CVHHIC'"61<J"P'3@UV^G\Z;:DG),*_R-<,1D8]:ZNSUBP2R@BEN%5E1
M0?D;T-95DWL1(RM?E=-4(#$#;V-91DD;AF)^IK1UNY@N]1\V!@R%<`A?2LRJ
MI_"./PB]O:E!*\J2/H<4E%44.\Z7_GJWYT&64@@R$CZTW%&*!6#M0>AHH/0T
M,9]H>&O^15T?_KRA_P#0!11X:_Y%71_^O*'_`-`%%?(U/C8SXOH-%!Z5]<(]
ME\-_!&RUWPWI^K2:U<PO>0+*8UB7Y=U:G_#/5C_T,%Y_WY6NX\((TOPFTM(U
M+.^E*JJO?Y*^;D\#^,-H!\.ZSG'/^CO7BTJU6I.:=7EL,[_7_@1J&G6,]YI6
MIK?N@W?9Y(=KGW5MWWJI^!?A):>+O"D>M/J\]LTK,OEQQ+_#7KWPVL-4TWP#
MI]KK"R+>)YA,<C?-&NYMJG\*I_"9H9?!#O!M^S-?W1BV_P!WS3M_2L98VLE)
M<U[.U["L?+*G<BMZC-+7M.G:+\&XKR#1FGN+V\+B$32/.%:3[O\`#M7K6/\`
M%?X<Z=X.MK34]):1;6>7R'@E?<4<*S*RM][^%J]2&-@Y*$DTWM<#R[WHP*]J
MT#P%X$T[PA%K/B>^2YG>W%Q)&MWM\M6&Y555;=NQ5CP[H7PE\:74NG:587L5
MVB%PKSS`X'=<NRFIEF%--V3:6[Z`>&]J*]&N/`%IHOQ<T[PU=/)=:?=%7`9B
MC/&VX$,R^ZUW7B7P-\,/"K6UUJZ7-O;R;D6W2>9S(WKP=WR_UIRQ]--))N^U
M@/G^BO;/''PT\-6_@[_A(O#J26ZJJ2A3+(ZS1MZAN5ZUMZI\+?`5CX<BU.]$
M^GQ(D4D]P+B1^#C(VMN^]TZ9YJ?[1I63L]78#YXQ17OF@>$OA1XO:XL]%AN&
MN84W,3+<*R@\;AO.WTK,O/!WPR\%71L_%&HW=Y>/ET3,H\M.W^KI_P!H0OR\
MKOVL!XM17N/B[X7^%CX)G\0^&5FMQ%!]H3]X[I,@Y(*O\U8_P]\`^%=4\.G6
M_$M^A+%BMM]K\H*J]SC#9H6/I.#G9^G4#R:C%>U:79_!C7]7BTFQL[L74[;(
MBTUP`S>QWUSOQ"^&J>&=>TVWTF21[74I!'$LIW/%)GH#W'>JAC82ERR35^X'
MF]'%>^7GPV^'W@G1X;GQ3+<7$DC>7YADE`=\9(58N?SI^D_#_P"&GC;3KEO#
MRW<,D)V/(DLV8W(R#B0D'\*AYA3M?E=N_09X!17HWA'X9-K7C'5='U*X=+32
MI-DYC7!D)/RA3[]3[5U&IZ?\%M!U*?2]06<W=NVV4"6Y;:1_NG;WJIXZFFHQ
M3?H(\1HKV7QM\+]`@\(OXG\+32BWCC6;8\A=)(R>JD_,#S5O0/AOX8O_`(6)
MKT]C(=1:Q><2K<R`!PIQ\H;':CZ_2Y5+SL,\0H^AP>QK>\$:7:ZWXTTC3K]#
M);7,VR1`^"1M8]N>HKT7Q[X*\%^$O$'A[=:RVVE7,CB^/GR.2H''5L]?3FM*
MN+A"?L[.XCS-_"NOQZ<=3DT:]2R$8D\_;\H0]_Q-8QP%)(X`Z5]=W_\`PCG_
M``KUA<F3_A'3:KD@R;O*XQ_M>GO7B/BQ/A2/#5W_`,(U)-_:J@>2&-QUSS]_
MY>E<^'Q[G=.+^7Z]AV':I\,-*T[P&^OQZ_YERELD_P!G^3EB0,9'/1J\Q[5[
MAKOPZ\,V/PHEUV#3Y5U!;&.<2&YD;#,5W?*6V\@TSPW\+/#-EX07Q%XNFE=6
MB$\B(YC2)3]W[G))!%32QD8Q;DV];;`>)48KWG0O#OP@\5WKZ=I%O<&[VEL>
M=<*<#ODG!K@/%/@`:!\0;3PZEZ/LMZ8Y(IYR%V1EBIWD\$C!Q713QM.4G%II
M^8K'"XP*,9X]>*]UU;PM\)_!UC;?VLTU_+(WEATNG:1B!GD1LH`Z5/IGPZ^'
M?CG0I[KPTMY9LCF(2&21MDFT'!#E@1@KTK/^T*>[B[=[`<!\-O`-OX\?4Q/?
M3V@M?*?:B9SO+<Y_X!7->*]#C\.>)[[2(YGF2UD\L2.N,\9KUSX"VLEEJ?BN
MTF`$L#P1R?+M^8-+S^(K//@FV\:_&OQ%;7\LB6=L1+(L9PSY(`&?0UE'%N->
M;<O=2"QXWVI:]N\1Z?\`"#POJ\FE:EIM])>1@-($EG.`WS`_?`[]A6;XN\&_
M#^3PI-J_AC5[>"Z2$7"6SWPD,B]UV,VX-V^M;0Q\9-7BTGUMH!Y%0>AHH/0U
MW,#[0\-?\BKH_P#UY0_^@"BCPU_R*NC_`/7E#_Z`**^1J?&QGQ?0>E%%?7"/
MK3P5*UM\+=&N``S1Z;'(N?\`<KR-?V@_$14'^R=)Y'I)_P#%5S5G\4O%>FZ/
M%HD5W;I;0P^0D9M58^7C^]]*XP+@#':O+H9?'GFZJO?8+GH6N_&3Q5K5C)8[
MK*QAF#K(UK&VXK_O,S?^.UZU\%ACX96W_7>;^=?,==?H?Q(\4>%]'73M-N+>
M.T1V**]NK'/\57B<%S4N2DDM;@<_X9_Y&#2/^OJ+_P!"6O?/V@!GP;I@/0ZF
M@/\`W[DKYYM)YK&[MY[=]LL,BLF?[W\-=)XE\?>(?%6G16>M7,4MO#,)E`@5
M#NVL/X?]DM55\-.=2$H[+<+GT!/:P>!/`JW?AGP\FH7,<,8$5O'^\G!VY=BJ
MEF_O5F^"?%.L^(_$)_M;P0VF&.)F2^>W>/:<\IN9>]>.:-\4_%N@:=%:VNHI
M+:PC:B74"OL']T,/F_.K;?&;QO+=QN-1MT(Z1+:KM;_>KC>`JZJR=^MPN=[X
MN_Y.'\-?]>\7_H<E4/VAA^]\/\=IOYI7G%[XX\0:AXEM_$5U-&VH62+&DJPJ
M$7EBN5_BY-0^*?&6M>*S:G7)HI#;[O)(@5-H;&?N_A6U'!U(5(2=K+<+E,Z]
MK$ULEA-J]^]D<1^0;AC'M!^[MW;:^A/BJ/\`BS4W_7.V_FM?-`X8,.HYKK-7
M^(WB7Q!H;Z+>W-O+:,$#*MLJ-A<;>?RKHQ&%E.I"4+63NPN=;^S]_P`C9J?_
M`%X_^U!61\;./B3<_P#7K%_6N8\,^*=5\*W<]YHLRI--%Y;LT*OP&']ZJ_B#
M7M1\1:O)J&J2JUVZJC,L2ID?\!H5"?UEU>EK!<^B(./@*3V_LD_R-0?#O1=.
MT7X:6FL:=I:7NI2VS3L57][,V3A`W;IC%>,#XE>)(?#O]@?:K=;'[.8#']F4
MML.<_-4?AKX@>)?"]J+/2M0;[.YWK#+$L@S[%N5KC>!JN,DGUOZA<]?T+QKX
MB\0^)+"TU7X?2P6QE'^DR6T@^S$9^?<Z;>/;UJ3XL74=KXB\&SRL%CCO\L3V
M[5YE/\9O&TQ1AJ$$*J<G9:IS^=8/BCQOKWBO[-'K5S'(+9BT16$(<X_V:J&!
MJ^T4FDEZA<]L^-V@:MKNA::VE6$]XT%P[21P1[W`*8R!7#>!?A+J^L07<VIS
M:CH>UAY2M#M9^.NUNE86E?%GQCHT"6L>I+/%&FV-+J!7P/3<,-^;&I;_`.,/
MC6[MGA;4(+9&!#-!;+N/XFJAA\53@Z4&K=PN>C?".V@TSQ+XLT9+MKF2WG7$
M[_>D4<;C^.:L^)/%WC72M>N[.R\#+?6BR'R+E()'$B>Y48!KP+2M8U/1]234
M-/O)H+P,1YJD$DGDY!X-=JOQM\:P1[9+JS<CC?):KN/X+Q2JX&I[1S5I:==/
MR"YZ?XHN?%T_PZU&XU.UT6RMGLLRP_O/,CSC(Y^7TJ[X(A>\^"MM!;+OEDT^
M1$4=2VT@#\Z\(\0_$'Q/XJMA9ZGJ`:W(W>1#$J(<=V[FF>&O'7B7PS;-!I%Z
M5LV.3!+&LD8/J`>1FI^H5?965D[W"YTOPU\#^);;QYI=W=Z+>6MM9R;YI;B+
MRUQM88'][D]:Z;]H;[NA]^)?Z5Q-W\7_`!M=O&YU*.`1'>$@MT`;ZYZBL;Q1
MXRUOQ;):IK<\4GV<MY6(53KU^[6T</7E652I;0+GO][;3ZK\$%@LH9+B>;2X
M_+CC&6?[IX'K7F$/PA*>`)_$&K7UU87<4$DK6<EO@+C[H.[G)XKGM$^)OBKP
MOIZ6%E>HUM&,I'<Q"3:,_P`)Z@>U,\0_$7Q5XFLFM-1OD%FY!:&VA6-9/<G[
MQQZ=*SIX7$TY-0:LW<+GMOBG/_"A)L#G^S(?YI4OB.TG\0_!)X-(C:YFGL(6
MACC/,@#*W'J<`UX9=?$GQ)?>'6T&XN;9K!H%A91;*&"+@CFF>&_B!XI\,6RV
M6E7["V`+BVEC21%'J"W(^E9K+ZUN96NG<+FKX/\`AEX@UC7S;W]IJFC0!&)N
MVMFC.<],]ZV#X$T_3_C!HGA^^U*758)8S/,MP,=%=EC(W'(X!Q_M5ES_`!K\
M;31E1=6D`QRR6PS7&3ZOJ=SK0U2:\N'U/S1()R^6#CG*GL/:NE4<5.3YVDO(
M+GTGXT\0ZGX.CM+3P_X/-_;R+AV@A8QQ@=`51:T?`.HWFK:3<7U_X:.A74ER
M0\1B,?G?*N),%0?;G^[7AMM\:/&T,:Q?;+:9@,!I+9=WU)[TQ?C)XXB>4G48
MW!8DAK2/"C':N1Y=6Y>6ROWN%ST3X/?\CCX\X_Y?$_\`1DU9NFPZVWQQ\3S:
M%<:>LT2@S0WH<)+'A.05[AL5YOH'C_7_``Y>:IJ&GR6XEU&42W+RP*06RQ&`
M.G+-5-O%VM'Q9-XCM[PP:I*V]I+=0JD'C!4\'Z&ME@JKE)Z:JP7/=]>\=^)=
M$U5]/G\!3:HJ!66YM#(T;D]0/W+=/K_#5C6M$TKQ9\.+K4]4\.1Z5>_8I9D6
M2,+-:LJL1E@%..,X/7TKR@?&[QK&@5[FQ..-TEL,GW^6LC7OB/XL\36$EK?Z
MB19O_K(8(UB5O0$CYB/8U$<!6YDTDK=;L+G(GC=MRWS%05Z$#O0>AHQQ0>E>
GRP/M#PU_R*NC_P#7E#_Z`**/#7_(JZ/_`->4/_H`HKY&I\;&?__9
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
